ロード中...
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy
Atomoxetine is a non-stimulant medication used to treat attention-deficit/hyperactivity disorder. CYP2D6 polymorphisms influence the metabolism of atomoxetine thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide the...
保存先:
| 出版年: | Clin Pharmacol Ther |
|---|---|
| 主要な著者: | , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6612570/ https://ncbi.nlm.nih.gov/pubmed/30801677 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.1409 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|